Literature DB >> 1345790

Multiple cytolytic mechanisms displayed by activated human peripheral blood T cell subsets.

M J Smyth1, Y Norihisa, J R Ortaldo.   

Abstract

It has been proposed that CTL-mediated cytotoxicity may involve multiple lytic mechanisms. We have examined both the antibody-redirected cytolytic potential and the direct cytotoxicity of purified human peripheral blood high buoyant density CD4+ and CD8+ T cells activated with IL-2 and anti-CD3 mAb. TNF-sensitive and TNF-resistant targets and various metabolic inhibitors were used to compare the antibody-redirected cytotoxicity of T cell subsets and discern the role of potential lytic mediators. In a 4-h assay against several different nitrophenyl-modified targets, the heteroconjugated antibody (anti-CD3-anti-nitrophenyl) redirected cytolytic potential of 72-h activated CD4+ T cells was inhibited by the continuous presence of actinomycin D, cycloheximide, and EGTA, but not mitomycin C, cyclosporin A, or cholera toxin (CT). Conversely, only CT and EGTA inhibited the antibody-redirected cytolytic potential of activated CD8+ T cells. Despite both CD4+ and CD8+ T cell subsets expressing granzymes, pore-forming protein, TNF-beta, and TNF-alpha, these T cell subsets displayed distinct pathways of antibody-redirected lysis against TNF-sensitive and TNF-resistant targets, even in the presence of anti-TNF antibodies. In addition, these same effector T cell subsets were also directly cytotoxic (in the absence of heteroconjugated antibody) against TNF-sensitive targets in an 18-h assay. Indeed, this direct cytotoxicity was completely abrogated by anti-TNF-alpha antibody and was sensitive to the metabolic inhibitors (cyclosporin A, CT, cycloheximide, and actinomycin D), all of which blocked CD4+/CD8+ T cell TNF-alpha production. Therefore, both CD4+ and CD8+ T cells were demonstrated to utilize antibody and lymphokine-mediated lytic mechanisms. CD4+ and CD8+ effector subsets were demonstrated to lyse the same TNF-sensitive target by these two different mechanisms. Although it cannot be excluded that the redirected lytic mechanisms of both CD4+ and CD8+ effectors share common elements, it is likely that other important events in this cytolytic process are fundamentally distinct between these subsets of T cells.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1345790

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  6 in total

1.  Target cell death triggered by cytotoxic T lymphocytes: a target cell mutant distinguishes passive pore formation and active cell suicide mechanisms.

Authors:  D S Ucker; J D Wilson; L D Hebshi
Journal:  Mol Cell Biol       Date:  1994-01       Impact factor: 4.272

Review 2.  The relative role of lymphocyte granule exocytosis versus death receptor-mediated cytotoxicity in viral pathophysiology.

Authors:  M J Smyth; J A Trapani
Journal:  J Virol       Date:  1998-01       Impact factor: 5.103

3.  IFN-alpha enhances peptide vaccine-induced CD8+ T cell numbers, effector function, and antitumor activity.

Authors:  Andrew G Sikora; Nina Jaffarzad; Yared Hailemichael; Alexander Gelbard; Spencer W Stonier; Kimberly S Schluns; Loredana Frasca; Yanyan Lou; Chengwen Liu; Helen A Andersson; Patrick Hwu; Willem W Overwijk
Journal:  J Immunol       Date:  2009-06-15       Impact factor: 5.422

4.  Unprimed CD4+ and CD8+ T cells can be rapidly activated by a CD3 x CD19 bispecific antibody to proliferate and become cytotoxic.

Authors:  I A Haagen; W B de Lau; B J Bast; A J Geerars; M R Clark; B C de Gast
Journal:  Cancer Immunol Immunother       Date:  1994-12       Impact factor: 6.968

5.  Distinct T cell receptor signaling requirements for perforin- or FasL-mediated cytotoxicity.

Authors:  M T Esser; B Krishnamurthy; V L Braciale
Journal:  J Exp Med       Date:  1996-04-01       Impact factor: 14.307

6.  Interleukin 2 receptor signaling regulates the perforin gene through signal transducer and activator of transcription (Stat)5 activation of two enhancers.

Authors:  J Zhang; I Scordi; M J Smyth; M G Lichtenheld
Journal:  J Exp Med       Date:  1999-11-01       Impact factor: 14.307

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.